3rd Annual Gene Therapy for Rare Disorders

Memo

Gene Therapy for Rare Disorders is a uniquely focused conference that will unite the leaders in this field to identify and discuss the critical factors that will influence genetic treatments most significantly in the near future.Bringing together leading experts from innovative biotechs, large pharma, academia and key service provider companies, Gene Therapy for Rare Disorders will present a comprehensive insight into the cutting edge progress of gene therapies combatting rare disease.Join 350+ of your colleagues to accelerate the progress of the next generation of gene therapies that show improved efficacy, enhanced safety and commercial viability.*Early bookings and group discounts are available upon request. For more information visit our website for the full pricing list. URLs:Tickets: https://go.evvnt.com/318111-2?pid=5569Brochure: https://go.evvnt.com/318111-3?pid=5569Price: Conference only (Early Bird): USD 2599.0Conference only (Standard): USD 2899.0Artists / Speakers: Derek Adams-Bluebird Bio, Robert Baffi-BioMarin, Brian Bronk-Sanofi, Jason Comander-Harvard Medical School, Chris Mason-AVROBIO, Troy Dale-Novartis, Olivier Danos-REGENXBIO, Jon Garen-uniQure, Kathleen Hehir-Sanofi Genzyme, Katherine High-Spark Therapeutics, Brian Kaspar-AveXis, Rune Kjeken-EMA, Ralph Laufer-Lysogene, Tim Miller-Abeona Therapeutics , Janet Lynch Lambert-Alliance for Regenerative Medicine, Peter Marks-FDA, Peter Saltonstall-NORD, Jude Samulski-UNC School of Medicine, Michael Sherman-Harvard Pilgrim Health Care Institute, Sam Wadsworth-UltragenyxTime: 9:00 am to 4:45 pmVenue details: The Westin Boston Waterfront, 425 Summer Street, Boston 02210, United States